Serial #87802745
LIVE

Serial Number

87802745

Owner

IOmx Therapeutics AG

Attorney

Allison R. Imber

Filing Date

Feb 19, 2018

Add to watchlist:

No watchlists yet
View on USPTO

Serial #87802745 Trademark

Serial Number: 87802745 • Registration: 5754567

Serial #87802745 is a trademark filed by IOmx Therapeutics AG on February 19, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

IOmx Therapeutics AG (5 trademarks)

Fraunhoferstr. 13

Entity Type: 99

Trademark Details

Filing Date

February 19, 2018

Registration Date

May 21, 2019

Published for Opposition

March 5, 2019

Goods & Services

[ Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases, disorders and conditions, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions ]

[ Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit; Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit; Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit ]

Scientific services, namely, scientific research, analysis and testing in the fields of biology, chemistry or medicine, as well as in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry; Scientific services, namely, scientific research, analysis and testing in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents, and diagnostic apparatus [ ; Design and development of computer software for database management, cloud-storage of data, data-management, data-query, data-analysis and data-presentation, for the query, analysis and presentation of the sequence or structure of molecules, or for predicting or providing a medical diagnosis or prognosis, as well as for controlling and managing patient medical information, with any of the aforementioned services for use in the fields of biology, chemistry or medicine, as well as for use in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry; Design and development of computer software for database management, cloud-storage of data, data-management, data-query, data-analysis and data-presentation, as well as for the query, analysis and presentation of the sequence or structure of molecules, or for predicting or providing a medical diagnosis or prognosis, with any of the aforementioned services for use in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents, and diagnostic apparatus ]

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Sep 30, 2025 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Sep 30, 2025 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 30, 2025 APRE
TEAS SECTION 8 & 15 RECEIVED
May 21, 2025 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
May 21, 2024 REM1
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 8, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Feb 8, 2024 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Feb 8, 2024 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 8, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 8, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 8, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 8, 2024 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 6, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 6, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 6, 2023 ECDR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Mar 6, 2023 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 6, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 6, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 6, 2023 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 8, 2021 TCCA
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Oct 8, 2021 EWOR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Oct 8, 2021 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 8, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 8, 2021 REAP
REGISTERED-PRINCIPAL REGISTER
May 21, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 5, 2019 NPUB
PUBLISHED FOR OPPOSITION
Mar 5, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 13, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 25, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 19, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 18, 2019 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jan 18, 2019 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 20, 2018 GNFN
FINAL REFUSAL E-MAILED
Dec 20, 2018 GNFR
FINAL REFUSAL WRITTEN
Dec 20, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 12, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 12, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 4, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 6, 2018 GNRN
NON-FINAL ACTION E-MAILED
Jun 6, 2018 GNRT
NON-FINAL ACTION WRITTEN
Jun 6, 2018 CNRT
ASSIGNED TO EXAMINER
Jun 4, 2018 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Apr 3, 2018 AMPX
ASSIGNED TO LIE
Mar 30, 2018 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Mar 16, 2018 PARI
NOTICE OF DESIGN SEARCH CODE E-MAILED
Feb 27, 2018 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 26, 2018 NWOS
NEW APPLICATION ENTERED
Feb 22, 2018 NWAP